Browse Articles

Discover research articles across all indexed journals

Radiographic progression without PSA progression in advanced prostate cancer patients.

Journal of Clinical Oncology Ruchi Chaudhary, Amitabha Bhaumik, Neeraj Agarwal et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.213

213 Background: Androgen Receptor Pathway Inhibitors (ARPIs) are frequently combined with Androgen Deprivation Therapy (ADT) to treat prostate cancer patients (pts) with castration sensitive (CSPC) or castration resistant (CRPC) disease. We sought to characterize pts who experienced radiographic progression without PSA progression (R-PD) while under treatment with ADT with or without an ARPI. Methods: We undertook a retrospective analysis of two phase 3 trials testing apalutamide (Apa) + ADT vs Placebo (Pbo) + ADT: TITAN (NCT02489318) in pts with metastatic CSPC (mCSPC) and SPARTAN (NCT01946204) in pts with non-metastatic CRPC (nmCRPC). We compared pts with R-PD with pts who experienced PSA progression before or concurrently with radiographic progression (PSA-PD). Kaplan-Meier and Cox proportional-hazard models were used to estimate time-to-event and hazard ratios. Results: The distribution of types of progression, and location of R-PD by study is shown in the table. Pts with R-PD had shorter overall survival (OS) compared with PSA-PD pts in both studies (median OS R-PD vs PSA-PD: 22.9 m vs 37.4 m in TITAN; 49.8 m vs 53.7 m in SPARTAN). Compared with Pbo, Apa delayed the time to R-PD in both studies (HR 0.51, 95% CI: 0.36 to 0.73 in TITAN; HR 0.17, 95% CI: 0.1 to 0.28 in SPARTAN). No pre-treatment variables predictive of R-PD vs PSA-PD were identified; transcriptional profile analysis is ongoing. Conclusions: Radiographic progression in the absence of PSA progression is not uncommon amongst patients with advanced prostate cancer, and carries a poor prognosis. The addition of Apa prolongs the median time to R-PD. Our findings underscore the importance of monitoring these pts with imaging, independent of PSA dynamics. The impaired survival of R-PD pts warrants evaluation of new therapeutic approaches for these pts. OVERALL TITAN (mCSPC; n=1052) SPARTAN (nmCRPC; n=1207) % pts with R-PD 12.4% 10.4% % pts with PSA-PD 41.2% 45.4% Sites of progression in R-PD pts (% of randomized pts) Bone only 6.3% 1% Non-bone 6% 8.8% Both 0.1% 0%

Effects of emerin dysregulation on the very-small-nuclear phenotype and neuronal differentiation and its association with a clinically aggressive subtype of prostate cancer.

Journal of Clinical Oncology Le Zhang, Pai-Chi Teng, Karen Angelica Cavassani et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.207

207 Background: Circulating tumor cells (CTCs) with a very-small-nuclear (vsn) phenotype (i.e., vsnCTCs) in prostate cancer (PCa) represent a distinct subset of CTCs characterized by nuclei smaller than 8.5 μm. Our previous studies established a link between vsnCTCs and the presence of visceral metastasis. Emerging evidence suggests that the reduction of emerin (EMD), a nuclear envelope protein, contributes to PCa metastasis and is associated with nuclear shape instability. This study aims to validate vsnCTCs as a biomarker in metastatic castration-resistant prostate cancer (mCRPC) and investigate the correlation between EMD expression and the vsnCTC phenotype. Methods: CTCs were isolated from 93 mCRPC patients using the NanoVelcro CTC assay and categorized as either vsnCTC-positive (vsnCTC+) or vsnCTC-negative (vsnCTC-). We compared overall survival (OS) and progression-free survival (PFS) between these two groups. In vitro experiments were conducted using PCa cell lines (C4-2B, 22Rv1, and DU145) with EMD knockdown via siRNA or shRNA to study its impact on cellular phenotypes. Additionally, we measured EMD expression and nuclear size in abiraterone- and enzalutamide-resistant (Abi-R/Enza-R) C4-2B cells. Results: vsnCTC+ patients had significantly worse OS and PFS compared to vsnCTC- patients. Multivariate analysis revealed that vsnCTC+ status was independently associated with poorer OS and PFS. EMD expression was markedly reduced in CTCs from vsnCTC+ patients compared to vsnCTC- patients, with a significant positive correlation between EMD expression and CTC nuclear size. EMD knockdown in PCa cells resulted in smaller nuclei, enhanced invasion, and the upregulation of genes associated with neuronal de-differentiation (e.g., SOX2, CHGA, MYCN, and AURKA). Additionally, C4-2B Abi-R/Enza-R cells had significantly smaller nuclei and lower EMD expression, consistent with our clinical observation of the vsnCTCs association with ARSI resistance. These resistant cells also demonstrated elevated expression of neuronal de-differentiation genes. Conclusions: The presence of vsnCTCs represents a novel hallmark of an aggressive subtype of mCRPC, closely linked to EMD dysregulation and neuroendocrine differentiation. These findings highlight the potential of vsnCTCs and associated biological changes as a predictive biomarker. Our findings underscore the importance of EMD in the progression and therapeutic resistance of advanced PCa.

Quality of Treatment Selection for Medicare Beneficiaries With Cancer

Journal of Clinical Oncology Aaron P. Mitchell, Sonia Persaud, Akriti Mishra Meza et al. Feb 10, 2025 DOI: 10.1200/jco.24.00459

PURPOSE The Medicare part D Low-Income Subsidy (LIS) improves access to oral cancer drugs, but provides no assistance for clinician-administered/part B drugs. This analysis assessed the association between LIS participation and receipt of optimal cancer treatment. METHODS We investigated initial systemic therapy using SEER-Medicare data (2015-2017) and National Comprehensive Cancer Network (NCCN) Evidence Blocks (EB) as the standard for treatment recommendations. We included cancer clinical scenarios wherein (1) ≥one treatment was optimal (higher efficacy and safety scores) versus other treatments; (2) identifiable in SEER-Medicare (eg, not defined by clinical data unavailable in registry data or claims); and (3) both EB and ASCO Value Framework agreed regarding optimal treatment. We fit logistic regression models to assess the association between receipt of systemic therapy ( v no therapy) and patient and provider characteristics. Contingent on receipt of treatment, we modeled the likelihood of receiving a treatment ranked (by EB scores) within the highest or lowest quartile for that cancer type. RESULTS Nine thousand two hundred and ninety patients were included across 11 clinical scenarios. Fifty-seven percent (5,336) of patients received any systemic therapy and 43% (3,954) received no systemic therapy. Compared with non-LIS participants, LIS participants were less likely to receive any systemic therapy versus no systemic therapy (odds ratio, 0.64 [95% CI, 0.57 to 0.72]). Contingent on receiving systemic therapy, LIS participants received treatment ranked within the worst quartile 24.8% of the time, compared with 21.9% of non-LIS patients (adjusted prevalence difference, 4.3% [95% CI, 0.5 to 8.2]). CONCLUSION LIS participants were less likely to receive systemic therapy at all and were more likely to receive treatments that receive low NCCN EB scores.

Intercellular bridges are essential for transposon repression and meiosis in the male germline

Nature Communications Julia Sorkin, Kevin Tilton, Matthew A. Lawlor et al. Feb 10, 2025 DOI: 10.1038/s41467-025-56742-9

Low-dose abiraterone in metastatic castration-resistant prostate cancer.

Journal of Clinical Oncology Julia Belone Lopes, Ana Elisa Sanches, Beatriz De Menezes Dobbert et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.164

164 Background: Abiraterone acetate (AA) is a selective and irreversible inhibitor of CYP17 approved for locally advanced and metastatic prostate cancer. The standard dose is 1000 mg orally while fasting. However, AA has a significant food effect, with serum levels increasing 5-7 times with a low-fat meal. Data suggest that a lower dose (250 mg with food, AALD) provides similar oncological outcomes to the standard dose, with a 75% cost reduction. In Brazil, 80% of patients are treated through the national public healthcare system, which does not afford AA in its label dose. Hospital de Base incorporated AALD since March 2021.Herein we present the data of patients with metastatic castration resistant prostate cancer treated with AALD. Methods: We retrospectively reviewed patients with mCRPC who received AALD at any treatment line, regardless of prior chemotherapy, from March 2021 to May 2023. The primary endpoint was PSA response rate (defined as a decrease of ≥ 50% in PSA concentration after 12 weeks of treatment). Secondary endpoints included time to treatment failure (TTF), overall survival (OS), and PSA response rate ≥ 50% at nadir. Data were summarized in medians, means and proportions. Chi-square was used for associations. Survival was calculated through Kaplan-Meier method. Cox-proportional hazards was used to compare groups. A p < 0.05 was considered statistically significant. Results: Ninety-six patients were included. The median age was 75 years (IQR 12.5), and most had an ECOG scoreof 1 (52.1%). Sixty-three patients (65.6%) received AALD in first-line, 26 (27.1%) in second-line, and 7 (7.3%) in third-line or beyond. The median PSA level before AALD was 20.9 (IQR 98.7). Twenty-seven patients (28.1%) had received docetaxel in mCRPC. After a median follow-up of 24.4 months, 53 patients (60.2%) had a ≥ 50% PSA response at 12 weeks, and 65 (69.9%) achieved a reduction of ≥ 50% at nadir. Patients treated with AALD pre-docetaxel had a higher PSA response at 12 weeks (68.3% vs. 40%, p = 0.015) and at nadir (76.1% vs. 53.8%, p = 0.036). First-line AALD was associated with better PSA responses. The median TTF was 7.9 months (5.5 – 10.3), and the median OS was 20.6 months (14.1 – 26). Achieving a ≥ 50% PSA response at 12 weeks was associated with improved TTF (13.6 vs. 4.6 months, HR = 0.37, p < 0.001) and OS (28.9 vs. 12.2 months, HR = 0.44, p = 0.004). Conclusions: AALD showed meaningful efficacy and survival outcomes. We advocate for AALD, particularly in settings where the standard dose is not affordable.

The Man Van phase 2 results: Mobile targeted case finding for prostate cancer.

Journal of Clinical Oncology Masood Moghul, Fionnuala Croft, Fiona Mutch et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.317

317 Background: Early intervention is potentially lifesaving in prostate cancer and is a major limitation of cancer outcomes with ethnicity and deprivation being determinants of inequalities that impact outcomes. The Man Van is designed to address health inequalities and barriers to accessing healthcare that affect prostate cancer with novel community-based targeting of high-risk groups using a mobile clinical unit. These inequalities are particularly relevant for men from ethnic minorities and lower socio-economic groups. Methods: A bespoke nurse-led mobile clinical unit was moved to community-based locations in areas of high deprivation indices in London (UK) with targeted invitations to high-risk men. Men were offered prostate-specific antigen (PSA) tests and a general health check including: blood pressure, body mass index and an HbA1c test for diabetes. Results: Between January 2023 and January 2024, 3379 men attended a Man Van clinic (non-attendance rate 15.1%). The median age of attendees was 59 years (range 39-97). 36.4% of attendees were non-White including 16.7% of men who were Black. The median IMD rank was within the 6 th lowest decile. 310 men were referred for prostate cancer investigations, 262 had prostate MRI scans. 139 (53.1%) of MRIs were PIRADS 1/2, 35 (13.4%) PIRADS 3, 85 (32.4%) were PIRADS 4/5. 3 (1.1%) scans could not be scored. 127 patients underwent a prostate biopsy (48.5% of men having an MRI scan), with 94 prostate cancers diagnosed (74.0% of biopsies). 81 (86.2%) of these were cancers with clinically significant disease, being grade group 2 (i.e. Gleason 7) or higher (all with >5% pattern 4 Gleason scores). The overall diagnostic rate of clinically significant disease was 2.8%. No prostate cancers were metastatic at presentation, with only one being T4. Of the men diagnosed with prostate cancer (N=94), 25 (26.6%) were managed with active surveillance, 2 (2.1%) were managed with cryotherapy, 2 (2.1%) were managed with low dose-rate brachytherapy, 39 (41.5%) underwent robotic prostatectomy and 26 (27.7%) underwent radiotherapy. 59 patients were referred on two week wait pathways for haematuria (visible or persistent non-visible). One bladder cancer (TCC) was diagnosed (G3pT1bN0M1). 43 patients (2%) were diagnosed with diabetes, 207 patients (11%) with pre-diabetes. Conclusions: The Man Van initiative is a novel method of linking primary and secondary care for a range of health checks, including PSA. With a streamlined and more efficient service we have maintained high uptakes for health checks a willingness to engage with health improvement measures from deprived and ethnic minority groups. As well as comparatively high levels of prostate cancers diagnosed at early stages, high levels of other health conditions were found; improving the economic value of the service. Clinical trial information: NCT06357416 .

Prevention, diagnosis, and management of penile cancer in the LGBTQ+ community: A systematic review and meta-analysis.

Journal of Clinical Oncology Akshit Chitkara, FNU Anamika, Atulya Aman Khosla et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.2

2 Background: Penile cancer is a rare but significant malignancy with unique prevention, diagnosis, and treatment challenges within the LGBTQ+ community. This systematic review and meta-analysis aims to evaluate the existing evidence on penile cancer for LGBTQ+ individuals, addressing disparities and unique needs to improve clinical outcomes. Methods: Following PRISMA 2020 guidelines, a systematic search was conducted across PubMed, Embase, Scopus, and clinical trial registries up to September 2024. Studies were included if they involved penile cancer prevention, screening, or treatment in LGBTQ+ populations, with no restrictions on study design or language. Data extraction focused on epidemiological patterns, risk factors (e.g., HPV infection), screening practices, diagnostic approaches, treatment modalities, and outcomes. The risk of bias was assessed using the Newcastle-Ottawa Scale for cohort studies and the Cochrane risk-of-bias tool for randomized controlled trials. The meta-analysis used a random-effects model to pool prevention and treatment outcomes data. Results: Of the 872 studies screened, 18 met the inclusion criteria, encompassing 1,232 LGBTQ+ patients. High-risk populations included men who have sex with men (MSM) and transgender women with elevated rates of HPV-associated penile cancer. HPV vaccination was underutilized in these populations despite its potential to prevent penile cancer. Early diagnosis was often delayed due to stigma, lack of awareness, and healthcare access barriers. Treatment outcomes varied, with higher rates of post-surgical complications and psychological distress reported. Meta-analysis revealed that HPV vaccination reduced the risk of penile cancer by 60% (pooled relative risk: 0.40, 95% CI: 0.25-0.64), while early surgical intervention improved 5-year survival rates by 45% (HR: 0.55, 95% CI: 0.32-0.79). Conclusions: Penile cancer prevention and management in LGBTQ+ populations require tailored strategies, including increased HPV vaccination coverage, early screening, and culturally competent healthcare. Addressing barriers related to stigma and healthcare access could significantly improve outcomes. Further research is needed to optimize treatment protocols and incorporate LGBTQ+-specific considerations in penile cancer care. Summary of meta-analysis results. Outcome Measure Number of Studies Pooled Effect Estimate 95% Confidence Interval (CI) Heterogeneity (I²) % HPV Vaccination Effectiveness 8 Relative Risk (RR): 0.40 0.25–0.64 42 Barriers to Early Diagnosis 5 Odds Ratio (OR): 2.25 (higher risk) 1.45–3.51 38 Post-Surgical Complication Rate 4 Risk Ratio (RR): 1.30 (higher rate) 1.12–1.50 27 Psychological Distress Post-Treatment 3 Standard Mean Difference (SMD): 0.75 0.50–1.00 60 5-Year Survival Improvement with Early Surgery 6 Hazard Ratio (HR): 0.55 0.32–0.79 49

EV-302: Updated analysis from the phase 3 global study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC).

Journal of Clinical Oncology Thomas Powles, Michiel Simon Van Der Heijden, Yohann Loriot et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.664

664 Background: EV-302 /KEYNOTE-A39 (NCT04223856) demonstrated significant progression-free survival (PFS) and overall survival (OS) benefit with first-line (1L) EV+P vs chemo in patients (pts) with la/mUC. EV+P is the standard of care (SOC) in global treatment guidelines for pts with untreated la/mUC. We present 12 mo of additional follow-up for EV-302 (>2 y of median follow-up) and an exploratory analysis of pts with confirmed complete response (cCR). Methods: Pts with previously untreated la/mUC were randomized 1:1 to receive EV (1.25 mg/kg; Days 1 and 8; IV) and P (200 mg; Day 1; IV) or gemcitabine with cisplatin or carboplatin every 3 wks. Dual primary endpoints were PFS by blinded independent central review (BICR) and OS. Select secondary endpoints were confirmed objective response rate (cORR), duration of response (DOR), and safety. An exploratory analysis evaluated treatment outcomes and safety in pts with cCR. Results: 886 pts were randomized to receive EV+P (n=442) or chemo (n=444). At data cutoff (Aug 8, 2024), median follow-up was 29.1 mo (95% CI, 28.5-29.9). PFS by BICR (HR, 0.48 [95% CI, 0.41-0.57]) and OS (HR, 0.51 [95% CI, 0.43-0.61]) were improved in the EV+P vs chemo arms (Table). OS benefit was seen irrespective of cisplatin eligibility or presence of liver metastases (mets). In the response-evaluable set, cORR was 67.5% for EV+P and 44.2% for chemo. Median DOR was 23.3 mo (95% CI, 17.8-not estimable [NE]) for EV+P and 7.0 mo (95% CI, 6.2-9.0) for chemo. 30.4% of pts in the EV+P arm and 14.5% in the chemo arm achieved cCR. Median duration of cCR was not reached for EV+P and 15.2 mo (95% CI, 10.3-NE) for chemo. Grade ≥3 treatment-related (TR) adverse events (AEs) in the EV+P vs chemo arms occurred in 57.3% vs 69.5% of pts in the safety analysis set (Table) and 61.7% vs 71.9% of pts in the cCR subgroup, respectively. TR deaths occurred in 1.1% vs 0.9% of pts in the safety analysis set in the EV+P vs chemo arms, respectively; none occurred in the cCR subgroup. Conclusions: EV+P continues to demonstrate superior efficacy vs chemo in a broad population, consistent with the primary analysis. Results confirm durable EV+P efficacy with no new safety signals, reinforcing EV+P as SOC for the 1L treatment of pts with la/mUC. Clinical trial information: NCT04223856 . Key efficacy and safety outcomes. EV+P Chemo EV+P vs chemo Efficacy (intent to treat set) n mo n mo HR (95% CI) Median PFS 442 12.5 (95% CI, 10.4-16.6) 444 6.3 (95% CI, 6.2-6.5) 0.48 (0.41-0.57) Median OS 442 33.8 (95% CI, 26.1-39.3) 444 15.9 (95% CI, 13.6-18.3) 0.51 (0.43-0.61) Cisplatin eligible 244 36.7 234 18.7 0.54 (0.42-0.70) Cisplatin ineligible 198 25.6 210 12.7 0.50 (0.39-0.64) Liver mets present 100 19.1 99 10.1 0.56 (0.40-0.78) Liver mets absent 342 39.3 345 18.3 0.50 (0.40-0.62) Safety (safety analysis set) n n Grade ≥3 TRAE 440 252 (57.3%) 433 301 (69.5%) –

ER-mitochondria contacts mediate lipid radical transfer via RMDN3/PTPIP51 phosphorylation to reduce mitochondrial oxidative stress

Nature Communications Isshin Shiiba, Naoki Ito, Hijiri Oshio et al. Feb 10, 2025 DOI: 10.1038/s41467-025-56666-4

Impact of loss of PRLHR on aneuploidy and initiation of bladder cancer.

Journal of Clinical Oncology Xi Zheng, Bingjie Yang, Wenya Wang et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.854

854 Background: The question still remains for the presence of yet unknown genetic modifiers in the initiation and/or progression of bladder cancer (BC). It remains challenging to identify the key factors, the mechanism and potential target behind. A genome-wide CRISPR library colony formation assay was performed using UROtsa cells, an immortalized ureter epithelium cell line, in order to identify novel genes that promote the transformation of normal urothelial cells. As one of the top candidate genes, the Prolactin Releasing Hormone Receptor (PRLHR) was identified. To date, only a few studies addressed the impact and the correlation of PRLHR in cancer and reports in the context of BC are missing altogether. Methods: We assessed the gene and protein expressions via public database, qPCR and Western blot analyses in a set of nontumour cell strains (Y235T, UROtsa) and a set of BC cell lines (RT4, T24). Following the shRNA knockdown in the PRLHR-proficient cells(Y235T) and the ectopic PRLHR expression in the cell lines with low/absent PRLHR expression(T24), we performed functional experiments, such as soft agar colony formation assay, MTT, invadopodia and gelatine degradation assays. We determined the invasion and migration abilities of these genetically modified cells by using the and wound-healing, Boyden chamber and porcine bladder ex vivo organ culture invasion assay. Metaphase spread assay and Immunofluorescence was performed in modified Y235T cells for chromosome counting and microscopy observation (centrsomes, chromosomal misalignments and lagging chromosomes). Results: The available in silico expression data and expression analyses in BC cell lines and matched normal/tumour patient samples revealed the repression of PRLHR early in BC tumorigenesis. Soft agar experiments confirmed that ectopic PRLHR impairs colony formation of T24 cells, providing indirect evidence that the CRISPR-Cas9 mediated deficiency of PRLHR promoted UROtsa cells transformation in the screening assay. Functional experiments using the MTT and the wound healing assays showed that ectopic PRLHR improved the viability and migration abilities of BC cells. The Boyden chamber assay and the porcine bladder organ culture model revealed that PRLHR impairs BC cell invasion, likely by the inhibition of the AKT/PKB pathway. Moreover, we observed an abnormal number of centrosomes, an increasing number of lagging chromosomes in the anaphase and telophase of the PRLHR-knockdown cells during mitosis. Conclusions: The screening procedure identified PRHLR as a new candidate tumour suppressor factor, and that loss/down-regulation of this protein contributes to the progression of bladder cancer. Downregulation of PRLHR leads to aneuploidy and genome instability in urothelial cells. PRLHR might serve as a novel biomarker or potential target for BC.

Global and regional burden of kidney cancer: Analysis and future predictions based on GBD data from 1990 to 2021.

Journal of Clinical Oncology Haochen Zhao, Qiang Wei Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.521

521 Background: Kidney cancer, as a common urological malignancy with poor prognosis, shows significant variations in incidence and mortality rates in different countries and regions worldwide. This study aims to investigate the global burden and trends of kidney cancer from 1990 to 2021, and to analyze its associations with various factors. Methods: First, data on the number of kidney cancer cases and age-standardized rates (ASR) of incidence, prevalence, mortality, and disability-adjusted life years (DALYs) from 1990 to 2021 were collected and analyzed globally. Subgroup analyses based on sex, country, region, and sociodemographic index (SDI) were then performed to examine the current status and time trends from 1990 to 2021 of kidney cancer in the total population and various subgroups. In addition, the age-period-cohort (APC) and Bayesian age-period-cohort analysis (BAPC) models were used to track dynamic changes in disease burden and predict future trends of the above indicators. Finally, risk factors and trend changes related to kidney cancer mortality within SDI subgroups were analyzed. Results: Globally, the incidence of kidney cancer increased sharply from 1.6×10 5 in 1990 to 3.9×10 5 in 2021. The ASRs for all measures of kidney cancer burden were higher for men than for women. China has the highest number of cases, deaths and DALYs in 2021, followed by the United States. The country of Cabo Verde and the region of Western Europe have the fastest growing ASRs for both incidence and mortality. 49 countries or regions, mainly in Western Europe and North America, have a decreasing trend in ASR for mortality over the period. Overall, the burden of kidney cancer increased with higher SDIs, with countries with middle and low-middle SDIs having the fastest growing burden of kidney cancer, such as North Africa and the Middle East. The APC and BAPC models predicted a steady decline in the ASRs of incidence, prevalence, mortality and DALYs for kidney cancer over the next 20 years, although the APC model predicted a continued steady increase in the absolute numbers of these indicators. In addition, high BMI and smoking were identified as the major risk factors contributing to kidney cancer deaths. High body mass index was particularly pronounced in countries with low SDIs. Conclusions: From 1990 to 2021, the incidence of kidney cancer has declined from historical peaks in developed countries, but remains on an upward trend in developing countries and represents a significant health threat. Revealing some previously unreported findings, the formulation of appropriate policies to reduce population exposure to risk factors associated with kidney cancer could be beneficial in the context of global aging trends.

PORTOS gene signature as a predictor of risk of adverse events after dose-escalated vs. lower-dose prostate radiation therapy in NRG/RTOG 0126.

Journal of Clinical Oncology Karen E. Hoffman, Sophia C. Kamran, Hyunnam Monica Ryu et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.375

375 Background: Dose-escalated radiation therapy is standard treatment for patients with prostate cancer. Dose-escalation improves cancer control but also increases the risk of treatment adverse effects. We hypothesized RNA-based tumor gene expression recapitulates normal tissue gene expression and therefore could identify patients at increased risk of adverse events after dose-escalated radiation. We specifically evaluated the 24-gene PORTOS score which characterizes response to DNA damage and radiation. Methods: PORTOS scores were calculated from biopsy samples obtained from 215 patients treated on the NRG/RTOG 0126 clinical trial that randomized patients with intermediate-risk prostate cancer between 70.2 Gy and 79.2 Gy delivered in 1.8 Gy fractions. In this trial, adverse events were categorized using RTOG criteria. Fine-Gray multivariable analysis of continuous and categorical PORTOS (tertiles) were used to calculate subdistribution hazard ratios (sHR), treating death without events as a competing risk, adjusting for age. Results: Median age was 70 years [IQR 65-74]. Fifty percent received 70.2 Gy (n=107), 50% received 79.2 Gy (n=108) and median follow up was 12.8 years. Patient and treatment characteristics were well balanced across treatment arms (all p>0.05) and across PORTOS groups (all p>0.05). Forty-five percent (n=97) of patients experienced grade 2 or higher adverse events after treatment. In patients receiving standard dose 70.2 Gy radiation, PORTOS was not associated with grade 2 or higher adverse events. However, in patients receiving dose-escalated 79.2 Gy radiation, higher PORTOS score was associated with a higher rate of grade 2 or higher adverse events (sHR = 1.12 [95% CI 1.03-1.22], p=0.01). There was a statistically significant interaction between continuous PORTOS scores and treatment arm for grade 2 or higher adverse events (p=0.01). Regarding treatment arm effects by PORTOS tertile, we observed that for patients with higher tertile PORTOS scores, dose-escalated radiation is more likely to cause grade 2 or higher adverse events compared to lower-dose radiation (sHR = 2.15 [1.04 - 4.44], p = 0.04; five-year cumulative incidence adverse events of 61% after 79.2 Gy vs. 36% after 70.2 Gy). In contrast, risk of grade 2 or higher adverse events was similar after treatment with dose-escalated vs. lower-dose radiation for patients with lower (p=0.41) or mid-tertile (p=0.78) PORTOS scores. Conclusions: HigherPORTOS scores were associated with an increased risk of adverse events after administration of dose-escalated radiation compared to standard-dose radiation. PORTOS is the first radiation sensitivity biomarker to be validated for toxicity with data from a phase III randomized trial and could be used to help personalize radiation therapy dose for patients to limit risk of treatment toxicity.

Impact of adherence to a remote exercise program on health-related quality of life in prostate cancer patients undergoing treatment: A prospective study in Brazil.

Journal of Clinical Oncology Paulo Gustavo Bergerot, Cristiane Decat Bergerot, Jonas Ribeiro Gomes Silva et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.130

130 Background: Patients with metastatic prostate cancer (mPCa) undergoing treatment often experience declines in health-related quality of life (HRQoL) and increased symptom burden. Exercise interventions are known to mitigate these effects, but adherence to such programs remains a challenge. This study aimed to assess the impact of adherence to a remote, home-based exercise program on HRQoL and symptom burden among patients with mPCa in a joint cancer practice in Brazil. Methods: This prospective study recruited patients with mPCa undergoing active treatment for both hormone sensitive and hormone resistant disease. Patients were assessed at baseline (T1) and after 12 weeks (T2) using the Functional Assessment of Cancer Therapy-General (FACT-G; scale: 0-108) and the Edmonton Symptom Assessment System (ESAS; scale: 0-90). Eligible participants received weekly exercise guidance through WhatsApp and performed prescribed exercise regimens (3 to 5 hours per week of combined resistance and aerobic training), with proper techniques demonstrated using the Vedius platform. Adherence was categorized as moderate to high (MH) ≥6 weeks of exercise, or low (L) ≤5 weeks. The primary outcomes included changes in HRQoL and symptom burden. Results: A total of 35 patients were recruited. The median age of participants was 74 years (range 58-91), with a majority being white (65.7%), married (82.9%), highly educated (88.6%), and retired (85.7%). All patients were receiving ADT plus abiraterone (34.3%), or docetaxel (25.7%), or enzalutamide (22.8%), or chemotherapy + abiraterone (14.3%). At 12 weeks, patients with moderate to high adherence demonstrated significant improvements in HRQoL (MH Mean T2 =94.9, L Mean T2 =88.7, P=0.01), particularly in physical (MH Mean T2 =25.1, Mean T2 =23.6, P=0.03), functional (MH Mean T2 =22.8, L Mean T2 =20.7, P=0.03), and emotional (MH Mean T2 =22.2, L Mean T2 =20.28, P=0.03) well-being domains, compared to those with low adherence. Additionally, those with higher adherence reported a lower symptom burden (MH Mean T2 =9.1 vs L Mean T2 =14.7, P=01). Conclusions: This study demonstrates that adherence to a remote exercise program significantly improves HRQoL and reduces symptom burden in patients with prostate cancer undergoing treatment. These findings underscore the importance of promoting exercise adherence through accessible platforms, such as WhatsApp, to enhance patient outcomes in mPCa.

Optimal low-depth quantum signal-processing phase estimation

Nature Communications Yulong Dong, Jonathan A. Gross, Murphy Yuezhen Niu Feb 10, 2025 DOI: 10.1038/s41467-025-56724-x

Abstract Quantum effects like entanglement and coherent amplification can be used to drastically enhance the accuracy of quantum parameter estimation beyond classical limits. However, challenges such as decoherence and time-dependent errors hinder Heisenberg-limited amplification. We introduce Quantum Signal-Processing Phase Estimation algorithms that are robust against these challenges and achieve optimal performance as dictated by the Cramér-Rao bound. These algorithms use quantum signal transformation to decouple interdependent phase parameters into largely orthogonal ones, ensuring that time-dependent errors in one do not compromise the accuracy of learning the other. Combining provably optimal classical estimation with near-optimal quantum circuit design, our approach achieves a standard deviation accuracy of 10−4 radians for estimating unwanted swap angles in superconducting two-qubit experiments, using low-depth ( < 10) circuits. This represents up to two orders of magnitude improvement over existing methods. Theoretically and numerically, we demonstrate the optimality of our algorithm against time-dependent phase errors, observing that the variance of the time-sensitive parameter φ scales faster than the asymptotic Heisenberg scaling in the small-depth regime. Our results are rigorously validated against the quantum Fisher information, confirming our protocol’s ability to achieve unmatched precision for two-qubit gate learning.

Platelet-to-lymphocyte ratio as a useful biomarker of recurrence and mortality risks in patients with muscle-invasive bladder cancer who achieved ypT0 to neoadjuvant chemotherapy: A multicenter retrospective study.

Journal of Clinical Oncology Naoki Fujita, Shogo Hosogoe, Toshikazu Tanaka et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.873

873 Background: Platelet-to-lymphocyte ratio (PLR), a novel inflammatory marker, has been suggested to predict recurrence and mortality in several malignancies. Patients with muscle-invasive bladder cancer (MIBC) who achieved a pathological complete response (ypT0) to neoadjuvant chemotherapy (NAC) have a favorable prognosis. However, the risk factors for recurrence and mortality remain unclear. Methods: This multi-institutional retrospective study assessed 950 patients with MIBC who underwent radical cystectomy (RC). Of the 950 patients, 128 patients who achieved a pathological complete response (ypT0) to 2–4 cycles of NAC were included. Univariable and multivariable Cox proportional hazards regression analyses were performed to identify the risk factors for recurrence and mortality. Results: The median age and follow-up period were 69 years and 80 months, respectively. Of the 128 patients, 15 (12%) and 30 (23%) experienced recurrence and died from any cause, respectively. The most frequent recurrence site was lymph nodes (n = 11, 73%), followed by urothelium (n = 4, 27%). The 10-year recurrence-free survival (RFS) and 10-year overall survival (OS) rates were 85.9% and 73.1%, respectively. In the univariable and multivariable analyses, clinical lymph node involvement, neobladder reconstruction, and PLR were independently and significantly associated with RFS (Table). In the univariable and multivariable analyses, age and PLR were independently and significantly associated with OS. Conclusions: Recurrence was not a rare event in patients with MIBC who achieved ypT0. PLR may be a useful biomarker to assess recurrence and mortality risks. Multivariable analysis for RFS. Factor P value Hazard ratio 95% CI Clinical lymph node involvement Positive 0.021 3.732 1.219–11.42 Urinary diversion Neobladder 0.281 0.281 0.094–0.842 PLR Continuous 0.029 1.003 1.000–1.006

Molecular subtypes, <i>NECTIN4/HER2</i> expression, and clinical outcomes in patients (pts) with advanced urothelial carcinoma (aUC) or muscle invasive bladder cancer (MIBC): Exploratory analyses from JAVELIN Bladder 100 and the Tempus database.

Journal of Clinical Oncology Markus Eckstein, Niklas Klümper, Petros Grivas et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.828

828 Background: Consensus molecular subtypes of UC/BC include basal/squamous (Ba/Sq), stroma-rich (SR), luminal unstable (lumU), luminal papillary (lumP), luminal nonspecified (lumNS), and neuroendocrine (NE)-like. Nectin-4 and HER2 are targets for novel antibody-drug conjugates. We report exploratory analyses of molecular subtypes, including NECTIN4 and HER2 RNA expression, in pts with aUC or MIBC from the JAVELIN Bladder 100 phase 3 trial and Tempus real-world database. Methods: JAVELIN Bladder 100 (NCT02603432) enrolled pts with aUC without progression after first-line platinum-based chemotherapy. Pts with MIBC or aUC were identified in the Tempus database of deidentified pt data from US clinical practice. Whole-transcriptome profiles in tumor samples were generated using RNA sequencing. NECTIN4 and HER2 transcript levels were quantified using Personalis ACE technology (JAVELIN Bladder 100) or kallisto (Tempus). Results: In evaluable aUC tumors from the JAVELIN cohort (n=560), NECTIN4 and HER2 RNA expression was heterogenous across molecular subtypes and was highest in lumU/lumP/lumNS subtypes and lowest in the NE-like subtype (Table); 57% of tumors had high (≥ median) expression of both NECTIN4 and HER2 RNA. Variations in NECTIN4 / HER2 RNA expression across molecular subtypes were similar in MIBC/aUC tumors from the Tempus cohort (n=501); 39% of tumors had high NECTIN4/HER2 RNA expression. In both cohorts, a strong correlation between NECTIN4 and HER2 RNA expression was observed overall (R=0.6-0.655), although correlation was not observed within all subtypes. In pts treated with avelumab in JAVELIN Bladder 100 (n=283; excluding NE-like [n=1]), no significant difference in overall survival was noted by molecular subtype (median [95% CI], mo: Ba/Sq, 27.2 [18.2-not estimable (NE)]; LumNS, 34.4 [20.8-NE]; LumP, 20.8 [18.2-31.4]; LumU, 24.9 [18.6-43.1]; SR, 28.8 [19.3-NE]). Limitations include exploratory analyses and potential selection bias. Conclusions: In these analyses, including the first analysis of consensus molecular subtypes in a phase 3 trial in aUC, NECTIN4 and HER2 RNA expression was heterogeneous across molecular subtypes of aUC and MIBC tumors and was highest in luminal subtypes. No significant difference in overall survival was noted across subtypes in pts treated with avelumab first-line maintenance. Clinical trial information: NCT02603432 . Subtype JAVELIN (n=560) Tempus (n=501) n (%) Expression level* n (%) Expression level* NECTIN4 HER2 NECTIN4 HER2 Ba/Sq 95 (17.0) 0.812 0.779 177 (35.3) 0.828 0.769 LumNS 30 (5.4) 1.029 0.905 30 (6.0) 0.990 0.926 LumP 135 (24.1) 0.984 0.888 89 (17.8) 0.962 0.925 LumU 95 (17.0) – – 99 (19.8) – – NE-like 3 (0.5) 0.152 0.460 37 (7.4) 0.311 0.613 SR 202 (36.1) 0.833 0.862 69 (13.8) 0.884 0.879 *Fold difference in transcripts per million vs LumU.

Radical prostatectomy (RP) versus radiotherapy (RT) in high-risk prostate cancer (HR-PCa): Emulated randomized comparison with individual patient data (IPD) from two phase III randomized trials (RCTs).

Journal of Clinical Oncology Soumyajit Roy, Yilun Sun, James Andrew Eastham et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.309

309 Background: Standard of care (SOC) treatment options for HR-PCa include RT with long-term androgen deprivation (LT-ADT) or RP with selective use of post-operative RT +/- androgen deprivation therapy (ADT). The optimal treatment approach has been assessed in retrospective population-based and multi-center comparisons, which have yielded mixed results with substantial bias. Therefore, we conducted an emulated randomized comparison of RT vs RP in HR-PCa leveraging patients enrolled in RCTs. Methods: We searched Medline for RCTs in HR-PCa with a SOC arm of an RT- or RP-based regimen. Inclusion required similar experimental treatment and contemporaneous enrollment in the same country to reduce bias. This identified 2 trials, NRG/RTOG 0521 (RT+LT-ADT +/- 6 cycles docetaxel [doce]), and CALGB 90203 (RP +/- neoadjuvant 6 cycles doce and ADT). Due to inherent difference in the biochemical recurrence criteria after RT vs RP, we chose inverse probability of treatment weighted (IPTW) cumulative incidence of distant metastasis (DM) as the primary endpoint, considering deaths as competing events. Death after DM was measured to create a harmonized metric of deaths likely attributed to PCa. To assess potential residual selection bias, death without DM to capture non-cancer associated deaths was analyzed. Results: Overall, 1290 patients (RT n=557, RP n=733) were included, with similar median follow-up of 6.4 years. Prior to IPTW, RP patients were significantly younger with lower baseline PSA compared to RT patients. Adjuvant (18%) and salvage therapy (44%) was used in RP cohort. Cumulative incidence of DM was significantly lower in patients who underwent RT compared to RP (8-year DM: 16% vs 23%; p=0.01; subdistribution hazard ratio [sHR] 0.48 [95%CI 0.34-0.69], p&lt;0.001). 8-year rates of death after DM were 10% vs 8% (p=0.72) in the RP and RT patients, respectively. RT patients had significantly greater risk of death without DM (HR 2.09 [1.01-4.34], p=0.048) with early differences measured. On a cross-arm comparison, 8-year cumulative incidence of DM when comparing SOC RT+LT-ADT group versus the doce+ADT+RP group was 18% vs 21%, respectively (sHR 0.75 [0.45-1.24], p=0.26). Conclusions: HR-PCa patients enrolled on RCTs had significantly lower incidence of DM with an RT-based strategy compared to an RP-based approach. Longer follow-up is needed to assess deaths attributed to PCa. Despite the strengths of the comparison (use of cooperative group RCT data, contemporaneous enrollment in the same country, patients fit enough for chemotherapy, and IPTW adjustments) there appears to be residual unmeasured bias, as expected, based on greater early deaths without DM in the RT arm. Utilization of post-operative radiotherapy and ADT+Doce may mitigate differences between RP and SOC RT+LT-ADT.

Protein analysis of urachal carcinoma tissue based on different antibody-drug conjugate therapeutic targets.

Journal of Clinical Oncology Tian Han, Honglei Cui, Xingang Bi et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.852

852 Background: Urachal carcinoma (UrC) is an extremely rare cancer, and there is still a lack of standard drug treatment models for advanced UrC. Antibody-drug conjugate (ADC) therapy represents a promising cancer treatment method. However, the efficacy of ADC on UrC remains unclear due to the scarcity of knowledge about the immunohistochemical features of relevant targets. This study focused on the immunohistochemical features of UrC based on ADC therapeutic targets and its relationship with overall survival (OS), providing a basis for UrC treatment. Methods: A total of 45 postoperative pathological specimens confirmed to be UrC were collected. Using immunohistochemistry, protein expression levels of ADC targets HER2, Nectin-4, Claudin18.2, Trop2, Mesothelin, and the immunotherapy target PD-L1 were assessed, with the proportion of high expression (2+ or 3+) of target proteins evaluated. 38 cases with complete clinical information were screened to evaluate the relationship between the expression of target proteins and OS. Results: Among the ADC therapeutic targets, Trop2 had the highest high expression rate (55.6%) in UrC tissues, followed by Mesothelin (46.7%), Claudin18.2 (31.1%), Nectin-4 (22.2%), and HER2 (15.6%). The high expression rate of PD-L1 was 15.6%. The median age of UrC patients was 53.5 years. Sheldon stage I, III and IV patients accounted for 2.6%, 89.5% and 7.9%, respectively. Survival analysis revealed that the five-year survival rate was 85.7% in the low Trop2 expression group and 49.2% in the high expression group. High expression of Trop2 was associated with poor OS (P=0.031). Conclusions: The target proteins of ADC are expressed in UrC tissue. Trop2 exhibits a significant high expression rate, and UrC patients with high Trop2 expression have a worse prognosis. Trop2 could be a pivotal target for future ADC treatment of UrC.

Multi-omics analyses reveal biological and clinical insights in recurrent stage I non-small cell lung cancer

Nature Communications Chengdi Wang, Jingwei Li, Jingyao Chen et al. Feb 10, 2025 DOI: 10.1038/s41467-024-55068-2

Immune checkpoint inhibitors in patients with testicular cancer: A systematic review.

Journal of Clinical Oncology Carlos Eduardo Salazar-Mejía, Estefanía Guadarrama-Rendón, Andrea Sarahi Guerra-Garza et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.638

638 Background: Germ cell tumors (GCT) are chemosensitive neoplasms with high cure rates, even in the metastatic setting. However, a small group of these patients will present tumors refractory to chemotherapy, with a dismal prognosis and very few effective management options. Although immune checkpoint inhibitors (ICIs) are approved for use in chemotherapy-refractory GCT for those tumors with a high microsatellite instability (MSI-H/dMMR) or high tumor mutational burden (TMB-H), the evidence supporting this indication is scarce. Methods: Original research studies, conducted on patients with GCT refractory to chemotherapy treated with ICI up to December 2023 were included. Comprehensive search strategies of 5 databases and MeSH keywords were used to locate eligible literature. Study characteristics, participant demographics, and oncological outcomes were recorded. Results: A total of 13 studies (n = 106) were identified for inclusion; 5 of which corresponded to single-patient case reports, one was identified as a retrospective cohort, 6 were phase II RCTs and we included a recent abstract from the preliminary results of a phase II RCT. Most of the studies evaluated did not request biomarkers as inclusion criteria. The median overall response rate across all patients included was 3.4% (range, 0-57), versus 0% (range 0-6) in those reported in retrospective cohort and phase II studies. Progressive disease as best clinical response was reported in most patients, with 75% (range, 0-82.9) in the overall population and 82% (range, 75 -83) in patients from retrospective cohort and phase II trials. Some of the most durable clinical responses documented in this systematic review corresponded to TMB-H or MSI-H/dMMR tumors. Conclusions: Analysis from retrospective cohorts and clinical trials evaluating ICIs for the treatment of chemotherapy-refractory GCT documented a limited activity of these drugs as a single intervention in patients not selected by biomarkers, with a tendency to better results described in those with TMB-H or MSI-H/dMMR tumors. Future prospective study designs should attempt to select patients by biomarkers to shed light on the determination of clinical and molecular factors that can predict response to ICIs in this scenario.